Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bufei Yishen Granule in GOLD Stage 3/4 COPD
NCT03976713Phase 3Unknown
- Sponsor
- Henan University of Chinese Medicine
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- TCM (Traditional Chinese Medicine), HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Bufei Yishen granule + Western medicine with Placebo + Western medicine (2 arms). Primary endpoints: Frequency of acute exacerbation at 52 weeks and Duration of acute exacerbation at 52 weeks. Status: unknown.
02
Drugs
bufei yishen granule
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03976713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976713.